Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
World game at war: why some European nations have threatened a World Cup boycott 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
EAST RUTHERFORD, N.J., April 19, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a commitment to provide its stockholders with additional information regarding its environmental, social and governance (ESG) practices. Cambrex’s commitment to the environment, health and safety underpins our activities across our sites. Over approximately the next 18 to 24 months, Cambrex will develop additional disclosures relating to our ESG related policies, strategies and performance. Once available, stockholders will be able to review these disclosures on Cambrex’s website at www.cambrex.com. In connection with today’s announcement, Trillium Asset Management, LLC informed Cambrex that it has withdrawn its shareholder proposal requesting the production of an ESG report from the agenda for the upcoming 2018 Annual Meeting of Stockholders. Cambrex has appreciated Trillium’s perspective on ESG matters and the feedback we received from our investors as part of our shareholder outreach effort.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing. For more information, please visit www.cambrex.com.
Contact:
Tom Vadaketh
Executive VP & CFO
Tel: +201 804 3033
Email: [email protected]
